ArticleFrontiers in nephrology2026
Age-specific impact of different immunosuppressive regimens on kidney transplant outcomes: clinical evidence from the scientific registry of transplant recipients.
Article in Frontiers in nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although older kidney transplant recipients have a higher risk of side effects leading to infection and malignancies, the impact of different immunosuppressive regimens on clinical outcomes in this group remains unclear. Methods: Retrospective cohort study analyzing data from the Scientific Registry of Transplant Recipients database. Kidney transplant recipients were categorized according to age categories (18-64 and >65 years) and immunosuppressive maintenance regimens: tacrolimus/mycophenolate mofetil (Tac-MMF), Tac/mTOR-inhibitor (Tac-mTORi), cyclosporin/MMF (CsA-MMF) and mTORi-MMF. The primary endpoint was overall survival. Results: Among the 112, 952 patients analyzed, overall survival rates at 2-, 3- and 5-years post-transplant were 95.6%, 93.7% and 87.6% respectively. No significant differences in the risk of mortality, graft loss or acute rejection were observed between patients treated with Tac-mTORi and those receiving Tac-MMF. Furthermore, no significant interactions were found between the maintenance immunosuppressive regimens and recipient age groups. Regarding kidney function, younger patients on the Tac-mTORi compared with Tac-MMF regimen exhibited a lower mean eGFR throughout the follow-up period compared to those on Tac-MMF. In contrast to this younger cohort, older patients treated with Tac-mTORi did not experience a significant additional decline in renal function. Conclusion: In this study, Tac-mTORi and Tac-MMF showed comparable results regarding patient survival, graft survival and rejection rates. Because older patients remain at higher risk for drug-related side effects, including infections, metabolic disorders and malignancies, these results highlight the critical need for individually immunosuppressive regimens in older transplant recipients and warrant further prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.